跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 58 条关于
“epNET”
全部
58
临床试验
46
药物
0
机构
0
资讯
12
去年
Cabozantinib Significantly Improves Progression-Free Survival in Advanced Neuroendocrine Tumors
2年前
Cabozantinib Shows Significant PFS Improvement in Advanced Neuroendocrine Tumors
2年前
Cabometyx Demonstrates Significant Efficacy in Advanced Neuroendocrine Tumors
2年前
Cabozantinib Shows Promise in Advanced Neuroendocrine Tumors in Phase III CABINET Trial
去年
FDA Foregoes Advisory Committee for Cabozantinib's Neuroendocrine Tumor Application
2年前
Cabometyx Demonstrates Significant Efficacy in Advanced Neuroendocrine Tumors
2年前
Cabometyx Demonstrates Significant Efficacy in Advanced Neuroendocrine Tumors
2年前
Cabometyx Demonstrates Significant Efficacy in Advanced Neuroendocrine Tumors
去年
Cabozantinib Shows Promise in Gastrointestinal Neuroendocrine Tumors: Phase 3 CABINET Subgroup Analysis
去年
Neuroendocrine Tumor Pipeline Shows Strong Growth with 75+ Therapies in Development
第 1 页,共 2 页
上一页
下一页